We called it had acquired resistance to Gefitinib. To explore the mechanism of Gefitinib acquired resistance after treatment, established human colon carcinoma LOVO/Gefitinib cell line and studied its characteristics.

• 为了探讨吉非替尼治疗中发生获得性耐药的机制,建立了人结肠癌吉非替尼耐药细胞系LOVO/Gefitinib,并对其生物学特性进行了研究,并初步探讨了P-糖蛋白(P-gp)和血管内皮生长因子(VEGF)与耐药的关系。